TruthArchive.ai - Related Video Feed

Dr. Hotez explains that while vaccines are often described as miraculous, the development was not a four-month process but a seventeen-year effort dating back to the post-SARS period. After SARS emerged in 2003, researchers identified the spike protein as the virus’s soft underbelly and began experimental vaccine development. When the COVID-19 sequence was released in January, the coronavirus community quickly concluded that a vaccine could be made, and attention turned to which technology would be fastest and most enduring. All vaccines discussed (AstraZeneca, Pfizer, Moderna, J&J, and the one being scaled in India) target the spike protein. He emphasizes that this was a deliberate long-term program, not a rushed push. Nicole notes the broader context of vaccine safety, particularly on a day when a vaccine-skeptical witness testified before the Senate Homeland Security Committee. Dr. Hotez clarifies that the virus behind the current pandemic comes from a family of coronaviruses scientists have studied for a long time, and that once specifics emerged, researchers could finalize the vaccine approach. He reiterates the importance of reassurance about safety in light of public skepticism. Dr. Hotez highlights the role of the NIH and the National Institute of Allergy and Infectious Diseases, led by Tony Fauci, and Francis Collins at NIH, in launching a major coronavirus program beginning in 2003. This funding enabled the development of some of the first prototype vaccines, illustrating a deliberate US government and NIH investment to advance vaccine research. He notes the ongoing need to assess rollout and production robustness, as this technology is brand new, and additional vaccines will be necessary to vaccinate populations. Looking ahead, the conversation acknowledges that the United States will require four or five different vaccines to achieve broad vaccination coverage, rather than relying solely on the two mRNA vaccines. The UK has begun vaccinations, marking an initial step, with plans to scale in the United States in the coming days. The discussion underscores a long road ahead to ensure scalable production, distribution, and multiple vaccine options to meet demand.

Many viruses use a 2-step authentication process to enter cells, involving binding to a receptor and spike protein cleavage. Virologists have been adding furin cleavage sites to viruses since 1992, increasing their virulence. SARS-CoV-2, which likely originated from nature, contains unique furin cleavage site codons not typical in coronaviruses. This suggests a low probability of natural origin.

We isolated coronaviruses from animals in the past to understand their threat to other species by culturing them on different cell types. This process, known as gain of function, involves enriching mutants that can infect new species. The speaker emphasizes that mass vaccination in humans is a significant gain of function experiment, leading to virus evolution. This real-world experiment involves constant virus changes due to human-to-human transmission under vaccine pressure.

Dr. Kizzmekia Corbett and her team have been studying spike proteins in viruses for the past 10 years. They discovered that controlling the spike protein's shape is crucial for creating effective vaccines. Using their knowledge from previous research on MERS coronavirus, they quickly applied their techniques to develop a vaccine for the current virus in collaboration with Moderna. By January 10th last year, they obtained the virus sequences and produced the vaccine over the weekend. They tested the vaccine on mice and found that it generated antibodies. Dr. Corbett mentions that they are now working on addressing the variants of the virus.

We created coronaviruses by assembling a synthetic bat genome with the SARS clone. The genome was split into 5 kilobyte pieces with unique restriction sites to allow directional assembly. Initially, the virus couldn't replicate due to an entry defect, so we replaced the receptor binding domain with one from the human epidemic strain. This modification resulted in a virus that replicated efficiently. The growth curve data supported this success.

We purchased spike protein subunit MFC tag from Sino Biological and prepared it using doubly distilled water. A stock solution (0.25 mg/ml) was created by adding 400 µl of diluent to 100 µg of spike protein. This was diluted to working solutions. We assessed different spike protein concentrations in platelet-poor plasma using fluorescence microscopy. A healthy blood sample was divided into four tubes with varying spike protein concentrations (1000, 100, 50, and 1 ng/ml). Samples were incubated for 30 minutes at room temperature. We're replicating this experiment. I'll extract blood, add PBS buffer, and the spike protein. Then we'll look at the fluorescence.

Here's a shorter version of the transcript: We're examining fluorescent micrographs of plasma from healthy individuals. We're looking at a PPP smear, a smear with added spike protein, and plasma exposed to spike protein. The goal is to see if adding spike protein creates larger microclots than in healthy blood. We'll be conducting an experiment to investigate this. A question was raised about whether blood type matters, specifically if O positive individuals have fewer reactions to COVID. While I'm not certain, it's something to consider.

Our study investigates the impact of the SARS-CoV-2 spike protein on blood hypercoagulation. We used microscopy and mass spectrometry to examine the spike protein's interaction with platelets and fibrinogen. Results using platelet-poor plasma showed the spike protein may disrupt blood flow. Mass spectrometry revealed structural changes in beta and gamma fibrinogen, complement, and prothrombin after adding spike protein S1. These changes, similar to those observed in COVID-19 patient blood clots, showed resistance to trypsinization. We propose that the spike protein's presence in the bloodstream contributes to hypercoagulation in COVID-19 patients, potentially causing impaired fibrinolysis and persistent microclots. This finding has significant clinical implications. Our goal was to determine the spike protein's effects, as its interaction with these blood components warrants further investigation.

This complex diagram highlights the presence of HIV in the spike protein, as identified by Luc Montagnier, a renowned virologist and Nobel Prize winner for discovering HIV. Montagnier found 18 RNA fragments that match HIV and Simian Immunodeficiency Virus (SIV). Notably, the PRRA sequence consists of four amino acids, requiring 12 nucleotides, indicating an insert rather than a mutation, which typically occurs one nucleotide at a time. Additionally, an HIV insert of 590 amino acids corresponds to 1,770 nucleotide bases that match HIV-1. This raises questions about the nature of these changes, as they cannot be explained as simple mutations. The evidence presented underscores significant findings related to HIV's presence in the spike protein.

The spike protein on the surface of the coronavirus is crucial for its structure and interaction with our cells. To trigger a strong antibody response, Keith replicates the spike protein in the lab. He uses a small piece of HIV protein as a clamp to lock the spike protein into its original shape. This ensures that the spike protein maintains its structure and effectiveness.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus, attenuated, or killed. Often, just a piece of the virus or the spike is used, eliminating the risk of causing disease. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which will end the pandemic.

Scientists sequence the virus and compare it to known pathogens like SARS. They discovered similar coronaviruses in bats and focused on the spike protein that attaches to cells. Chinese researchers created pseudoparticles with spike proteins from these viruses to test their binding to human cells. Each step of this process helps determine if the virus can become pathogenic in humans. Manipulating the spike protein in the lab is crucial for understanding the zoonotic risk. By obtaining the sequence, scientists can predict the virus's behavior more accurately.

Ohio State University scientists published research exploring the incorporation of a coronavirus antigen into the measles, mumps, rubella (MMR) vaccine to produce COVID-19 immunity in children. The study used a modified live attenuated mumps virus for delivery and a more stable prefusion version of the SARS-CoV-2 spike protein (6P). Experiments showed the 6P antigen induced significantly more neutralizing antibodies in mice and hamsters than the 2P version used in existing mRNA and adenovirus-based COVID-19 vaccines. The modified mumps vaccine generated high levels of the 6P protein, triggering a strong immune response and protection from lung damage. The 6P vaccine induced neutralizing antibodies and T-cell activity against several variants of concern. Researchers also explored intranasal delivery, which induced IgA antibodies on mucosal surfaces of the airways, potentially offering superior protection compared to injected vaccines. The findings suggest existing immunity to mumps may slow initial antibody stimulation but does not prevent a strong protective response. The study also claims that adenoviruses, adeno-associated viruses, and lentivirus are used in gene therapy for cancer therapy, vaccines, and COVID-19 vaccines.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus, attenuated, or killed, or just a piece of the virus or the spike. A promising new method is the RNA vaccine, which uses RNA and DNA to provide instructions to make the spike shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible to everyone, which is how the pandemic will end.

Okay, let's get started. I need to find the right tools to draw blood, so please be patient. I'll put the scope back on so we can watch. Here are some micrographs: healthy predlopod plasma, then the same plasma with spike protein added. We want to see if adding spike protein directly to healthy blood creates larger microclots than we see in the samples with the spike protein already present. We'll compare the images to see the effects.

The spike protein of the coronavirus plays a crucial role in triggering a strong antibody response. To study it in the lab, Keith uses a small fragment of HIV as a clamp to lock the spike protein into its original shape. This helps maintain the structure of the virus on its surface.

The speaker explains that the spike protein on the coronavirus is crucial for its structure and interaction with our cells. To trigger a protective antibody response, Keith replicates the spike protein in the lab and locks it into the same shape using a clamp-like protein. Surprisingly, this clamp-like protein is a small fragment of HIV.

Dr. Yeason presents three principal assertions about the vaccines. 1) The first principle: we were told these molecules were gene sequences that encoded something called the spike protein. The spike protein is described as on the outside of the virus, and vaccines were said to encode the protein to train the immune system. Dr. Yeason explains that the immune system treats anything foreign as a threat and will attack cells that manufacture a foreign protein, leading to tissue damage. He notes that this principle of “self, non self” and tissue targeting is fundamental to organ transplantation and autoimmune diseases, and says this was designed into every company’s molecule (Moderna, Pfizer, Johnson & Johnson, AstraZeneca). He asserts that by 2020 he knew these were designed to cause injury. 2) The second principle: what was encoded is the spike protein. He states he did not know what spike protein was at first, but describes spikes on the outside of the virus and claims they are known toxins (neurotoxins, cardiotoxins) that prompt blood coagulation. He questions why a medicinal product would encode something that would harm the body when expressed. 3) The third principle: lipid nanoparticles (LNPs) used to formulate two of the Pfizer and Moderna products. He explains that lipid nanoparticles are toxic in general and are known to promote uptake of their payload into visceral organs, especially the liver and ovaries. He asserts that when injected into women and girls, these materials would travel through the body, concentrate in reproductive organs, be expressed, be recognized as foreign, and kill those cells. He asks what possible motivation there could be for using that formulation when other options exist. This, he says, confirms that the first two observations were not mere risks but intentional design. Dr. Yeason concludes that these three points together indicate that someone in a room designed injections to injure, kill, and reduce fertility in the people given them, aiming to lower fertility and reduce the population over time. He states he has observed this “all around me for five years since that moment.”

Researchers have discovered various coronaviruses in bats, including ones similar to SARS. They focused on the spike protein, which attaches to cells, and conducted experiments in China. By inserting spike proteins from these viruses into pseudoparticles, they tested their ability to bind to human cells. This process allowed them to understand the potential pathogenicity of the virus in humans.

Bonjour à tous, Anaïs Bloqué, docteur en biologie santé, explique les impacts de la protéine Spike du SARS-CoV-2 sur le système immunitaire inné, basés sur son article récent. La Spike seule n'active pas complètement le TLR 4, un récepteur immunitaire, et ne produit pas d'interférons de type 1, essentiels pour la réponse antivirale. Pour une activation complète, la Spike doit s'associer au LPS (des bactéries Gram négatif). L'activation des interférons 1 augmente l'expression d'ACE2, le récepteur du virus, via les ISG, sensibilisant l'organisme à l'infection. Les ARN messagers des vaccins peuvent aussi lancer la production d'interférons 1 via MDA5. La Spike, protéine amyloïde, peut aussi déclencher le TLR 4 avec des fibres amyloïdes, entraînant un "double effet amyloïde". L'augmentation de NF-κB par les ISG peut bloquer la p53, potentiellement cancérigène. De plus, NF-κB induit le MIR-200c, qui bloque l'ACE2. Chez les individus avec comorbidités, une boucle d'amplification inflammatoire se crée : Spike-LPS-TLR4 induit interférons 1, ISG, surexpression d'ACE2, augmentation de NF-κB, MIR-200c, diminution d'ACE2 et augmentation d'angiotensine 2. La Spike persiste longtemps, et ses propriétés amyloïdes font craindre des pathologies dégénératives à long terme. --- Hello everyone, Anaïs Bloqué, PhD in health biology, explains the impacts of the SARS-CoV-2 Spike protein on the innate immune system, based on her recent article. Spike alone does not fully activate TLR 4, an immune receptor, and does not produce type 1 interferons, which are essential for the antiviral response. For complete activation, Spike must associate with LPS (from Gram-negative bacteria). Activation of interferon 1 increases the expression of ACE2, the virus's receptor, via ISGs, sensitizing the body to infection. Vaccine mRNAs can also trigger the production of interferon 1 via MDA5. Spike, an amyloid protein, can also trigger TLR 4 with amyloid fibers, leading to a "double amyloid effect." The increase in NF-κB by ISGs can block p53, which is potentially carcinogenic. In addition, NF-κB induces MIR-200c, which blocks ACE2. In individuals with comorbidities, an inflammatory amplification loop is created: Spike-LPS-TLR4 induces interferon 1, ISG, ACE2 overexpression, increased NF-κB, MIR-200c, decreased ACE2 and increased angiotensin 2. Spike persists for a long time, and its amyloid properties raise concerns about long-term degenerative pathologies.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus (attenuated), a killed virus, or just a piece of the virus, like the spike. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which is how the pandemic will end.

In the lab, it's easy to manipulate spike proteins, which play a significant role in the zoonotic risk of coronaviruses. By obtaining the sequence and constructing the protein, we collaborated with Ralph Barrick at UNC to insert it into another virus. This allows us to conduct experiments and enhance our ability to predict outcomes based on specific sequences.

We focus on viral families that have transmitted from animals to humans. When we find a virus that resembles a known dangerous pathogen, like SARS, we examine its spike protein, which attaches to cells. Chinese researchers create pseudo particles with these spike proteins to test if they bind to human cells. This process helps us identify viruses that could potentially be harmful to humans. By narrowing down the field and reducing costs, we end up with a small number of viruses that appear to be dangerous. We then investigate if people living in the same region as the animals carrying these viruses have developed antibodies.